Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8310)	5/9/2003 11:35:08 AM
From: A.J. Mullen	Read Replies (1) \| Respond to of 52153

In the same spirit but opposite direction, let's consider the reduction in the cost of research. High through-put has reduced the cost of screens dramatically. Genomics allows for targeting of molecular structures. What's been the effect? Is it cheaper to get a drug to the clinic? Certainly there are a lot more companies doing it now, but there's no flood of new drugs. I imagined more drugs for smaller markets. That doesn't seem to be happening. Figures were produced sometime ago in defence of the FDA that suggested there had been a decline rather than an increase in submissions. What gives? Is the effect similar to the introduction of word-processors in offices - more and better produced memos, but no discernible effect on productivity? Ashley